Pre-made Afutuzumab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-013-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name	Afutuzumab
Target	CD20
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	3pp3:HL:IK/3pp4:HL
99% SI Structure	6y9a:HL
95-98% SI Structure	6y97:HL
Year Proposed	2008
Year Recommended	2011
Companies	GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds
Conditions Approved	Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma
Conditions Active	Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia
Conditions Discontinued	Primary biliary cirrhosis
Development Tech	GlycoMAb Technology